Century Therapeutics
IPSC
47 hedge funds and large institutions have $25.6M invested in Century Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 16 closing their positions.
153% more capital invested
Capital invested by funds: $10.1M → $25.6M (+$15.5M)
5.91% more ownership
Funds ownership: 23.5% → 29.42% (+5.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less funds holding
Funds holding: 57 → 47 (-10)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.64M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.12M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$665K |
| 4 |
Two Sigma Investments
New York
|
+$357K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.76M |
| 2 |
Renaissance Technologies
New York
|
-$755K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$448K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$165K |
| 5 |
Squarepoint
New York
|
-$118K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Marshall Wace
London,
United Kingdom
| – | -$27.1K | -54,161 | Closed |
|
|
BCM
52
Bluefin Capital Management
New York
| – | -$12K | -24,018 | Closed |
|
|
HF
53
HRT Financial
New York
| – | -$9K | -18,113 | Closed |
|
54
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$8.71K | -17,501 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$6.53K | -13,116 | Closed |
|
|
JG
56
Jain Global
New York
| – | -$5.6K | -11,241 | Closed |
|
57
AQR Capital Management
Greenwich,
Connecticut
| – | -$5.31K | -10,660 | Closed |
|
|
ASN
58
Advisory Services Network
Atlanta,
Georgia
| – | -$203 | -407 | Closed |
|
59
Morgan Stanley
New York
| – | -$59 | -118 | Closed |
|
|
EWA
60
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$14 | -28 | Closed |
|
|
IA
61
IFP Advisors
Tampa,
Florida
| – | -$3 | -6 | Closed |
|
62
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1 | -2 | -3% |
|
IPSC Hedge Fund Activity: Q4 2025 in Review
47 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2025, worth a combined $25.6M — up 153% from $10.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IPSC and 8 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.64M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.76M sold.
- 47 institutional investors held Century Therapeutics (IPSC) as of Q4 2025, down from 57 in Q3 2025.
- Funds reported $25.6M of Century Therapeutics stock for Q4 2025, up 153% quarter-over-quarter.
- 8 funds opened new Century Therapeutics positions in Q4 2025 and 16 closed out, a net change of -8 holders.
- The largest Century Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $3.64M added.
- The largest Century Therapeutics seller in Q4 2025 was Bain Capital Life Sciences Investors, an estimated $1.76M sold.
Based on aggregated 13F filings for Q4 2025.